IMPACT OF OBESITY ON THE ONCOLOGICAL AND SURGICAL OUTCOMES OF THIGH SOFT TISSUE SARCOMA

O. Hamdy¹, Kh. Atallah¹, M.H. Ros², I.H. Metwally¹

Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt.
E-mail: omarhamdy87@gmail.com¹
Mansoura University Hospitals, Mansoura, Egypt²

Abstract

Background. Malignant soft tissue tumors are a heterogeneous group with variable prognosis and with a tendency to recurrence and distant spread, mainly to the lungs. Also, obesity is a known risk factor for many diseases and cancers and is currently a global problem. While the thigh is one of the main fat deposition areas, it is one of the commonest sites for the incidence of soft tissue sarcoma. We tried to illustrate the impact of obesity on the outcomes of thigh soft tissue sarcoma patients. Material and Methods. We retrospectively recruited data of extremity sarcomas treated at our hospital from January 2008 to January 2020. The epidemiological and clinical data of all the included patients was analyzed, then the surgical and oncological outcomes between obese and non-obese patients were compared (defining obesity as BMI more than 30). We hypothesized that fat deposition in the thigh in obese patients may delay the diagnosis of soft tissue sarcoma, lead to the discovery of the masses at a larger size and stage, and hence may affect the disease-free survival and the overall survival.

Results. Obese patients had significantly larger size tumors (median: 14.7 vs 9.9 cm) and as such significantly higher T stage. Another significant finding was that the mean diameter of liposarcoma tumours was 15.1 cm, while that of non-liposarcomas was 11.3 cm (p-value=0.023). Also, although they did not have a higher prevalence of distant metastasis at initial diagnosis, their metastasis tends to be isolated in the lung. Postoperative complications occurred more frequently in obese patients in comparison to non-obese patients (p-value=0.025). Neither overall nor disease-free survivals were different among both groups, although obese patients tend to have shorter DFS.

Conclusion. Obesity added complexity to the diagnosis and treatment of extremity sarcoma, but seems not to affect survival.

Key words: soft tissue tumours, extremity tumours, obesity, survival.

ВЛИЯНИЕ ОЖИРЕНИЯ НА ОНКОЛОГИЧЕСКИЕ И ХИРУРГИЧЕСКИЕ РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ САРКОМЫ МЯГКИХ ТКАНЕЙ БЕДРА

О. Хамди¹, Х. Аталла¹, М.Х. Рос², И.Х. Метвалли¹

Отделение хирургической онкологии, онкологический центр Университета Мансуры, Мансура, Египет. E-mail: omarhamdy87@gmail.com¹
Университетские больницы Мансуры, Мансура, Египет²

Аннотация

Актуальность. Злокачественные опухоли мягких тканей являются гетерогенной группой опухолей с различным прогнозом и тенденцией к частому рецидивированию и отдаленному метастазированию, преимущественно в легкие. Ожирение представляет собой глобальную проблему, являясь известным фактором риска многих заболеваний, в том числе злокачественных новообразований. Хотя бедро представляет собой одну из основных областей отложения жира, оно является одним из наиболее
Introduction

Soft tissue sarcomas (STS) are rare neoplasms of mesenchymal origin that can occur at any anatomical site, but the most common sites are the extremities. STS are highly aggressive with a high risk of developing distant metastasis, and their management should be carried out on a multidisciplinary basis in specialized centers. The best management scenario includes wide excision of the primary with maximal functional preservation of the limb, in addition to perioperative radiotherapy and/or chemotherapy in indicated cases [1–3]. Early diagnosis of extremity STS is crucial for the success of the treatment plan [4].

Meanwhile, obesity is an expanding epidemic that has a negative impact on cancer patients leading to increased incidence of some cancers and poorer treatment outcomes. While the thigh is one of the main fat deposition areas, it is one of the commonest sites for the incidence of soft tissue sarcoma [5, 6].

We hypothesized that fat deposition in the thigh in obese patients may delay the diagnosis of soft tissue sarcoma, lead to the discovery of the masses at a larger size and stage, and hence may affect the disease-free survival and the overall survival.

Material and Methods

This is a retrospective study, where the institutional registry at our Center, was thoroughly revised for thigh soft tissue sarcoma cases that attended the hospital from January 2008 to January 2020.

The inclusion criteria were 1) Pathological proven soft tissue sarcoma. 2) The thigh was the primary site. 3) BMI was recorded. Patients were excluded if pathology is uncertain or insufficient data were found on the registration system.

We analyzed the epidemiological and clinical data of all the included patients, then we compared the surgical and oncological outcomes between obese and non-obese patients (defining obesity as BMI more than 30)

Results

Out of the total number of sarcoma patients treated in our center (more than 330), the study included 41 patients diagnosed with thigh sarcoma. Females were dominating (24: 17). The mean age at diagnosis was 47.7 years, while the mean BMI was 32.1. The most common pathological subtype was liposarcoma followed by synovial sarcoma.

Eleven patients were initially treated by systemic therapy. Bearing in mind that 8 of them were metastatic as such receiving on palliative bases, the neoadjuvant therapy was infrequently used (3 patients only). Moreover, the therapy used was dominantly chemotherapy only, except in 1 patient where combined chemoradiotherapy was given.

All operated cases even those with clinically positive nodes turned node negative in the final paraffin sections.

After a median follow-up for 13 months (0–47), recurrence was infrequent (3 cases) and all recurrences were combined local and distant, affecting the lungs in all cases, in addition to non-regional nodes in 2 cases. The clinical and pathological data of the included patients were summarized in Table 1.

The body mass index showed a linear correlation to the tumor size (Pearson correlation coefficient=0.691,
### The clinical and pathological data of the included patients

#### Клинические и патологические данные пациентов

| Parameter/Параметр | Value/Значение |
|-------------------|----------------|
| Age, years/Возраст, лет | 47,7 ± 19,1 |
| BMI/Индекс массы тела | 32,1 ± 8,0 |
| Gender/Пол | |
| Male/Мужской | 17 (41,5 %) |
| Female/Женский | 24 (58,5 %) |
| **Histopathologic type/Гистотип** | |
| Liposarcoma/Липосаркома | 15 (36,6 %) |
| Synovial sarcoma/Синовиальная саркома | 11 (26,8 %) |
| Pleomorphic sarcoma/Плеоморфная саркома | 4 (9,8 %) |
| Leiomyosarcoma/Лейомиосаркома | 4 (9,8 %) |
| Rhabdomyosarcoma/Рабдомиосаркома | 2 (4,9 %) |
| Spindle cell sarcoma/Веретеноклеточная саркома | 2 (4,9 %) |
| Epithelioid sarcoma/Эпителиоидная саркома | 1 (2,4 %) |
| Malignant peripheral nerve sheath/Злокачественная опухоль оболочек периферического нерва | 1 (2,4 %) |
| Peripheral neuroectodermal tumour/Периферическая нейроэктодермальная опухоль | 1 (2,4 %) |
| T stage/T стадия | |
| T1 | 2 (4,9 %) |
| T2 | 14 (34,1 %) |
| T3 | 13 (31,7 %) |
| T4 | 12 (29,3 %) |
| Clinical N stage/Клиническая N стадия | |
| N0 | 33 (80,5 %) |
| N1 | 8 (19,5 %) |
| Pathologic N stage/ypN стадия | |
| M0 | 33 (80,5 %) |
| M1 | 8 (19,5 %) |
| Isolated lung metastasis/Метастазы в легкие | 4 (50,0 %)* |
| Lung & non-regional nodes/Метастазы в легкие и нерегионарные лимфоузлы | 2 (25,0 %)* |
| Lung & liver metastasis/Метастазы в легкие и печень | 1 (12,5 %)* |
| Lung & brain metastasis/Метастазы в легкие и головной мозг | 1 (12,5 %)* |
| **Primary therapy/Предоперационная терапия** | |
| No/Нет | 30 (73,2 %) |
| Yes/Да | 11 (26,8 %) |
| Chemotherapy alone/Химиотерапия | 10 (90,9 %)* |
| Chemoradiotherapy/Химиолучевая терапия | 1 (9,1 %)* |
| **Surgery/Операция** | |
| No/Нет | 8 (19,5 %) |
| WLE | 29 (70,7 %) |
| WLE & lymph node dissection/WLE и лимфодиссекция | 3 (7,3 %) |
| Above-knee amputation/Ампутация выше колена | 1 (2,4 %) |
| **Complications**/Осложнения | |
| No/Нет | 15 (36,6 %) |
| Yes/Да | 14 (34,1 %) |
| **Adjuvant therapy/Адъювантная терапия** | |
| No/Нет | 7 (17,1 %) |
| Yes/Да | 26 (63,4 %) |
| Radiotherapy/лучевая терапия | 18 (69,2 %)* |
| Chemoradiotherapy/Химиолучевая терапия | 8 (30,8 %)* |
| **Recurrence in operated patients/Рецидивы после операций** | |
| No/Нет | 28 (63,3 %) |
| Yes/Да | 3 (7,3 %) |

Notes: * – valid percent; ** – available registered data.

Примечания: * – допустимый процент; ** – доступные зарегистрированные данные.
Obese patients had significantly larger size tumors (mean 14.7 vs 9.9 cm, p-value=0.002) and as such significantly higher T stage (11 patients diagnosed with T4 tumors vs only one patient in the non-obese group) according to AJCC 8th edition (p-value=0.035). Also, although they did not have a higher prevalence of distant metastasis at initial diagnosis, their metastasis tends to be isolated in the lung. Another significant finding was that the mean diameter of liposarcoma tumors was 15.1 cm, while that of non-liposarcomas was 11.3 cm (p-value=0.023).

In addition, postoperative complications occurred more frequently in obese patients in comparison to non-obese patients (p-value=0.025). The commonest complication in obese patients was wound dehiscence followed by seroma. Complications were mostly Clavien-Dindo (CD) 3 and 4, however; there was no significant difference either in type or CD grade of complications between the two groups. Neither overall nor disease-free survivals were different among both groups, although obese patients tend to have shorter DFS (fig. 2, 3). The comparison between the group of obese and non-obese patients is summarized in Table 2.

**Discussion**

Soft tissue sarcoma is a rare category of neoplasms that accounts for about 1% of adult malignant tumors. It occurs mainly in the extremities, trunk, and retroperitoneum. STS family includes many pathological subtypes exhibiting various clinical presentations and necessitating different approaches for management putting into consideration the molecular and histological characteristics, clinical presentation, staging, and other patient-related factors. Management
The comparison between the group of obese and non-obese patients
Сравнение между группами пациентов с ожирением и без ожирения

| Parameter/Параметр | Obese/Ожирение (n=24) | Control/Контроль (n=17) | Significance/Значимость |
|-------------------|-----------------------|-------------------------|--------------------------|
| Age mean, years/Средний возраст, лет | 52.0 ± 16.5 | 41.6 ± 21.3 | 0.086 |
| Gender/Пол | Male/Мужской 7 (29.2 %) 10 (58.8 %) 0.12 | Female/Женский 17 (70.8 %) 7 (41.2 %) | |
| Histopathologic type/Гистотип | Liposarcoma/Липосаркома 11 (45.8 %) 4 (23.5 %) 0.19 | Others/Другие 13 (54.2 %) 13 (76.5 %) | |
| Tumour size mean, cm/Средний размер опухоли, см | 14.7 ± 5.4 | 9.9 ± 3.0 | 0.002 |
| T stage/Т стадия | T1 1 (4.1 %) 1 (5.9 %) | T2 5 (20.8 %) 9 (52.9 %) 0.035 | |
| | T3 7 (29.2 %) 6 (35.3 %) | T4 11 (45.8 %) 1 (5.9 %) | |
| N stage/Н стадия | N0 18 (75 %) 15 (88.2 %) 0.43 | N1 6 (25 %) 2 (11.8 %) | |
| | M0 18 (75.0 %) 15 (88.2 %) 0.43 | M1 6 (25 %) 2 (11.8 %) | |
| M stage/М стадия | Lung metastasis/Метастазы в легкие 4 (66.7 %) | Lung & non-regional nodes/Метастазы в легкие и нерегионарные лимфоузлы 2 (33.3 %) 0.46 | |
| | Lung & liver metastasis/Метастазы в легкие и печень – 1 (50.0 %) | Lung & brain metastasis/Метастазы в легкие и головной мозг – 1 (50.0 %) | |
| Primary therapy/Предоперационная терапия | No/Нет 15 (62.5 %) 15 (88.5 %) 0.085 | Yes/Да 9 (37.5 %) 2 (11.8 %) | |
| Surgical treatment/Хирургическое лечение | No/Нет 6 (25.0 %) 2 (11.8 %) | WLE 15 (62.5 %) 14 (82.3 %) 0.52 | |
| | WLE & LND/WLE и лимфодиссекция 2 (8.4 %) 1 (5.9 %) | AKA/Ампутация выше колена 1 (4.1 %) – | |
| Adjuvant therapy/Адъювантная терапия | No/Нет 7 (30.4 %) 4 (21.7 %) 1 | Yes/Да 16 (69.6 %) 11 (73.3 %) | |
| Postoperative complications/Послеоперационные осложнения | No/Нет 5 (31.3 %) 10 (76.9 %) 0.025 | Yes/Да 11 (68.7 %) 3 (23.1 %) | |
| | Seroma/Серома 3 (27.3 %) 2 (66.7 %) 0.62 | Bleeding/Кровотечение 1 (9.1 %) – | |
| | Wound dehiscence/Расхождение раны 6 (54.5 %) 1 (33.3 %) | Infection/Инфекция 1 (9.1 %) – | |
| Clavien–Dindo score of complications/Степень тяжести по Clavien–Dindo | I 1 – | II 4 2 | 0.77 |
| | III 5 1 | IV 1 1 | |
| Recurrence/Рецидив | No/Нет 14 (87.5 %) 14 (93.3 %) 1 | Yes/Да 2 (12.5 %) 1 (6.7 %) | | 0.16 |
| Overall survival/Общая выживаемость | 18.6 months/мес | 37.1 months/мес 0.096 | |

The pathological subtype is considered an important prognostic factor in addition to the tumor grade and size. Old patient’s age, margin status, and the deep location of the tumor affect prognosis as well [3, 7, 9–11]. The most common pathological subtype in our group was liposarcoma followed by synovial sarcoma.

of STS is preferably carried out on a multidisciplinary basis in specialized centers [7, 8].

Nearly, 40–60 % of STS occur in the extremities. 80 % of extremity STS occur in the lower limb. The most common pathological subtypes are undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, epithelioid sarcoma, and synovial sarcoma. The pathological subtype is considered an important prognostic factor in addition to the tumor grade and size. Old patient’s age, margin status, and the deep location of the tumor affect prognosis as well [3, 7, 9–11]. The most common pathological subtype in our group was liposarcoma followed by synovial sarcoma.

CIROVSKII ONKOLOGICHESKIY ZHURNAL. 2022; 21(1): 91–98
Management of extremity STS is built on MDT decision. The cornerstone for management in non-metastatic cases is a wide-margin oncolgic resection that preserves the limb function. Amputation is reserved for non-candidates for limb-sparing surgery after neoadjuvant therapy or for local recurrent selected cases. Preoperative or postoperative radiation is recommended in stages II, IIIA & IIIB. Neoadjuvant and adjuvant chemotherapy is not the standard of care, but it can be considered in selected cases. Isolated limb perfusion/infusion may have a role in locally advanced non-metastatic tumors [7–10, 12–15]. Upfront surgery with wide margins following a limb preserving strategy was the most common intervention performed in our patients’ group.

Extremity soft tissue sarcoma usually presents as a painless mass with a slow rate of growth. The gradual size progression is the single most important warning sign. Large size more than 5 centimeters, pain, being deep to the deep fascia, and recurrence after resection are important alarms as well [9, 16]. In our research, we hypothesized that obesity may hinder palpation of the mass and may delay the discovery of deep masses leading to the presentation of the disease at a more advanced stage the body fat deposition may mask the discovery of the swelling [11].

Obesity is a major health problem with increasing incidence worldwide. It affects -along with overweight-more than one-third of the world population. Obesity is considered the second leading cause of preventable death in the United States after cigarette smoking. This increasing incidence led to considering obesity as an “epidemic” disease which led to many health and economic challenges. Obesity increases the risk of chronic disease incidence and morbidities such as diabetes mellitus, depression, cardiovascular diseases, shortened life expectancy, and mortality. It is linked also to increased incidence of some cancers as well as cancer-related complications. Body mass index (BMI) is used as an acceptable index to define obesity which starts from a BMI of more than 30 [17–21]. In our locality, the prevalence of obesity reaches up to 46 % in females and 22 % in males [22].

The thigh is considered one of the body fat stores which include the abdominal and the subscapular areas as well [6]. We supposed that being a fat store, the fat deposition in the thigh may hinder the discovery of small-sized soft tissue masses leading to a delayed discovery of soft tissue sarcoma. That was clear as regards the size of tumors at the initial discovery in obese versus non-obese patients. Obese patients present with larger-sized tumors and a higher T stage. Also, the larger diameter of liposarcoma tumors VS. non-liposarcomatous tumours can share in explanation of the greater size of the tumors in the obese group being more of the lipocyte originating sarcoma type.

Obesity has been related to poorer outcomes in patients with extremity soft tissue sarcoma as STS in obese patients is associated with larger tumor sizes, increased surgical complexity, and complications [10]. It has been reported to increase the incidence of STS as well [23, 24]. Despite the effect on incidence, Alamanda and his colleagues reported that there was no negative impact on survival for obese patients with extremity soft tissue sarcoma [5]. The same results were confirmed by Houdek et al. and Montgomery et al., who reported that obesity does not have a negative impact on functional and oncological outcomes, but they reported an increased incidence of postoperative infection and wound complications in morbidly obese patients necessitating re-admission to the operative theater with the possibility of increased perioperative morbidity and even mortality [11, 24]. In our study, obesity did not affect overall survival or disease-free survival. Yet, obese patients tend to have shorter disease-free survival and coping with published literature – a higher incidence of postoperative complications.

Our study has limitations; being retrospective, the relatively low number of patients, the non-uniform treatment protocols over the years, and the absence of the measurement of thigh circumference.

Conclusion
Obese patients with thigh soft tissue sarcoma present with larger-sized tumors, a significantly higher T stage, a tendency for isolated lung metastasis, and a higher rate of perioperative complications. Overall survival and disease-free survival are not affected by BMI, although obese patients tend to have shorter disease-free survival.

Ethical approval & consent to participate
All procedures performed in the study were following the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. This is a retrospective study for which a specific ethical committee approval is not needed.

Availability of data and materials
All the clinical, radiological & pathological data used in this manuscript is available on our University database medical system.

ЛІТЕРАТУРА/REFERENCES
1. Hasley I., Gao Y., Blewins A.E., Miller B.J. The Significance of a «Close» Margin in Extremity Sarcoma: A Systematic Review. Iowa Orthop J. 2018; 38: 123–30.
2. Jacobs A.J., Michels R., Stein J., Levin A.S. Improvement in Overall Survival from Extremity Soft Tissue Sarcoma over Twenty Years. Sarcoma. 2013; 2015: 279601. doi: 10.1155/2015/279601.
3. Atean I., Pointreau Y., Rosset P., Garaud P., De-Pinieux G., Calais G. Prognostic factors of extremity soft tissue sarcoma in adults. A single institutional analysis. Cancer/Radiothérapie. 2012; 16(8): 661–6.
4. Park J.H., Kang C.H., Kim C.H., Chae I.J., Park J.H. Highly malignant soft tissue sarcoma of the extremity with a delayed diagnosis. World J Surg Oncol. 2010; 8: 84. doi: 10.1186/1477-7819-8-84.
5. Alamanda V.K., Moore D.C., Song Y., Schwartz H.S., Holt G.E. Obesity does not affect survival outcomes in extremity soft tissue sarcoma. Clin Orthop Relat Res. 2014; 472(9): 2799–806. doi: 10.1007/ s11999-014-3714-7.
6. Karastergiou K., Smith S.B., Greenberg A.S., Fried S.K. Sex differences in human adipose tissues – the biology of pear shape. Biol Sex Differ. 2012; 3(1): 13. doi: 10.1186/2042-6410-3-13.
7. Gamboa A.C., Gronchi A., Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020; 70(3): 200–29. doi: 10.3322/caac.21605.

8. Casali P.G., Abeccassis N., Arro H.T., Bauer S., Biagioni R., Bielack S., Bonvalot S., Boukinaia I., Bovee J.V.M.G., Brodovicz T., Broto J.M., Buonadonna A., De Ataiva E., Dei Tos A.P., Del Muro X.G., Dileo P., Eriksson M., Fedonenko A., Ferraresi V., Ferrari A., Ferrara S., Frezza A.M., Gerspoch S., Geldevich H., Gil T., Grignani G., Gronchi A., Haus R.L., Haug B., Hohenberger P., Issels R., Joensuu H., Jones R.L., Judson I., Jutte P., Kaal S., Kasper B., Kopeckova K., Kráková D.A., Le Cesne A., Lugowska I., Merinsky O., Montemurro M., Pantaleo M.A., Piana R., Petti P., Piperno-Neumann S., Pousa A.L., Reichardt P., Robinson M.H., Rutkowski P., Safwat A.A., Schöffski P., Sleijfer S., Stacchiotti S., Sundby Hall K., Unk M., Van Caeveloorn F., van der Graaf W.T.A., Whelan J., Wardemann M., Zaikova O., Blay J.Y.; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29: doi: 10.1093/annonc/mdy096.

9. Puri A., Gulia A. Management of extremity soft tissue sarcomas. Indian J Orthop. 2011; 45(4): 301–6. doi: 10.4103/0019-5413.82332.

10. Brinkmann E.J., Ahmed S.K., Houdek M.T. Extremity Soft Tissue Sarcoma: Role of Local Control. Curr Treat Options Oncol. 2020; 21(2): 13. https://doi.org/10.1007/s11864-020-0703-9.

11. Montgomery C., Harris J., Siegel E., Stiva L., Wilson M., Morell S., Nicholas R. Obesity is associated with larger soft-tissue sarcomas, more surgical complications, and more complex wound closures (obesity leads to larger soft-tissue sarcomas). J Surg Oncol. 2018; 118(1): 184–91. doi: 10.1002/jso.25119.

12. Stevenson M.G., Musters A.H., Geertszen J.H.B., van Leeuwen B.L., Hoekstra H.J., Been L.B. Morbid Obesity Is Associated With an Increased Risk of Wound Complications, and More Complex Wound Closures (Obesity Leads to Larger Soft-tissue Sarcomas). J Surg Oncol. 2018; 117(3): 434–42. doi: 10.1002/jso.24881.

13. Byerly S., Chopra S., Nassif N.A., Chen P., Sener S.F., Eisenberg B.L., Teeng H.W. The role of margins in extremity soft tissue sarcoma. J Surg Oncol. 2016; 113(3): 333–8. doi: 10.1002/jso.24212.

14. Al-Refaie W.B., Habermann E.B., Jensen E.H., Tuttle T.M., Pisters P.W., Virmig B.A. Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity. Br J Surg. 2010; 97(5): 707–13. doi: 10.1002/bjs.6946.

15. Endo M., Lin P.P. Surgical margins in the management of extremity soft tissue sarcoma. Chin Clin Oncol. 2018; 7(4): 37. doi: 10.21037/cco.2018.08.10.

16. Umer H.M., Umer M., Qadir I., Abhassi N., Masood N. Impact of unplanned excision on prognosis of patients with extremity soft tissue sarcoma. Sarcoma. 2013. doi: 10.1155/2013/498604.

17. Hales C.M., Carroll M.D., Fryar C.D., Ogden C.L. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. 2020; (360): 1–8.

18. Wang Y., Beydoun M.A., Min J., Xue H., Kaminsky L.A., Cheskin L.J. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020; 49 (3): 810–23. doi: 10.1093/ije/dyz273.

19. Wolin K.Y., Carson K., Colditz G.A. Obesity and cancer. Oncologist. 2010; 15(6): 556–65. doi: 10.1634/theoncologist.2009-0285.

20. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterol Clin North Am. 2010; 39(1): 1–7. doi: 10.1016/j.gtc.2009.12.014.

21. Hruby A., Hu F.B. The Epidemiology of Obesity: A Big Picture. Pharmaco economics. 2015; 33(7): 673–89. doi: 10.1007/s40273-014-0243-x.

22. Alehshuey R., Shaub N.M., Mbako J.D., Barfio D., Nuotol R.K. Determinant Analysis of Obesity among Adult Females in Egypt. Egypt J Hosp Med. 2016; 65(1): 662–9. doi: 10.12816/0033779.

23. Tavani A., Soler M., La Vecchia C., Negri E., Gallus S., Franceschi S. Body weight and risk of soft-tissue sarcoma. Br J Cancer. 1999; 81(5): 890–2. doi: 10.1038/sj.bjc.6690781.

24. Houdek M.T., Hevesi M., Griffin A.M., Wunder J.S., Ferguson P.C. Morbid Obesity Is Associated With an Increased Risk of Wound Complications and Infection After Lower Extremity Soft-tissue Sarcoma Resection. J Am Acad Orthop Surg. 2019; 27(21): 807–15. doi: 10.5435/JAAOS-D-18-00536.

The authors declare that they have no conflict of interest.

This study required no funding

The authors declare that they have no conflict of interest.
Ислам Х. Метвалли, MD, MRCS, член Королевской коллегии хирургов, Отделение хирургической онкологии, онкологический центр Университета Мансура (Мансура, Египет). Author ID (Scopus): 57142135100. ORCID: 0000-0002-5981-9614.

ВКЛАД АВТОРОВ

Омар Хамди: разработка концепции научной работы, сбор и обработка данных, статистическая обработка, составление черновика рукописи.
Халид Аталла: анализ научной работы, критический пересмотр с внесением ценных интеллектуальных содержаний.
Мохамед Х. Рос: анализ научной работы, критический пересмотр с внесением ценных интеллектуальных содержаний.
Ислам Х. Метвалли: анализ полученных результатов, статистическая обработка.

Финансирование
Это исследование не потребовало дополнительного финансирования.

Конфликт интересов
Авторы заявляют об отсутствии конфликта интересов.